STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B

STAT PlusBiotech Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B The deal will expand the Italian pharma company’s work in the U.S. Manage alerts for this article Email this article Share this article By Andrew JosephMay 7, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71.

The Italian company Angelini Pharma said Thursday it would buy the rare-disease focused Catalyst Pharmaceuticals for roughly $4.1 billion in cash. The deal values Florida-based Catalyst at $31.50 a share, a 28% premium to the 30-day period before April 22, when it became publicly known that a deal was in the works. Advertisement Buying Catalyst, which sells three approved medicines, will give Angelini a foothold in the U.S.

market. It also builds on its work in neurology. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, rare disease, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew Joseph covers health, medicine, and the biopharma industry in Europe.

You can reach Andrew on Signal at drewqjoseph.71. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended The Readout May 6, 2026 STAT Plus: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price Biotech May 6, 2026 STAT Plus: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field Advertisement The Readout May 5, 2026 STAT Plus: Are analysts too quick to gloss over Lilly’s liver case? Biotech May 5, 2026 STAT Plus: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease Biotech May 5, 2026 STAT Plus: Johnson & Johnson advances IBD therapy, despite trial miss Subscriber Picks